Tumor Biology

, Volume 35, Issue 4, pp 3067–3071 | Cite as

Prognostic role of microRNA-100 in various carcinomas: evidence from six studies

  • Jie Chen
  • Biqiang Zheng
  • Chunmeng Wang
  • Yong Chen
  • Chunyan Du
  • Guangfa Zhao
  • Ye Zhou
  • Yingqiang Shi
Research Article


Recent studies have shown that microRNAs (miRNA) exhibit altered expression levels in cancers, and they may be considered as valuable prognostic biomarkers for patients with cancers. We performed this meta-analysis to provide a comprehensive evaluation of the role of miRNA-100 expression on the overall survival rate by calculating the pooled hazard ratio (HR) for overall survival (OS), which compared the high and low expression levels of miR-100 in patients of the available studies. Finally, a total of six studies dealing with various carcinomas were involved for this meta-analysis. The results indicated that lower expression of miR-100 in cancerous tissue could significantly predict poorer survival in various carcinomas with the pooled HR of 2.19 (95 % CI 1.49–3.24, P = 0.0007). In conclusion, the findings from this present meta-analysis suggest that miR-100 expression is associated with OS in cancer patients and could be a useful clinical prognostic factor for those patients.


MicroRNA-100 Cancer Prognosis Meta-analysis 


Conflicts of interest



  1. 1.
    Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 2011;3:140–55.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Osman A. MicroRNAs in health and disease—basic science and clinical applications. Clin Lab. 2012;58:393–402.PubMedGoogle Scholar
  3. 3.
    Roberts AP, Lewis AP, Jopling CL. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci. 2011;102:101–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D, et al. Microrna-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene. 2012;31:4509–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. Microrna-148a suppresses tumor cell invasion and metastasis by downregulating rock1 in gastric cancer. Clin Cancer Res. 2011;17:7574–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Berardi E, Pues M, Thorrez L, Sampaolesi M. MiRNAs in ESC differentiation. Am J Physiol Heart Circ Physiol. 2012;303:H931–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring, and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143–59.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Roy S, Sen CK. MiRNA in wound inflammation and angiogenesis. Microcirculation. 2012;19:224–32.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6:590–610.PubMedCrossRefGoogle Scholar
  10. 10.
    Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis, and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012;7:e33762.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX. Microrna-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 2012;12:519.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microrna-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27:1238–44.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al. Reduced expression of microrna-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Chen P, Zhao X, Ma L. Downregulation of microrna-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383:49–58.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang G, Chen L, Meng J, Chen M, Zhuang L, Zhang L. Overexpression of microrna-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol. 2013;45:373–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Bai J, Guo A, Hong Z, Kuai W. Upregulation of microrna-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012;5:213–9.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.PubMedCrossRefGoogle Scholar
  18. 18.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, et al. Microrna-143 targets macc1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012;11:23.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Hong L, Han Y, Li S, Yang J, Zheng J, Zhang H, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary, and pancreatic carcinomas. Expert Opin Biol Ther. 2010;10:1693–701.PubMedCrossRefGoogle Scholar
  22. 22.
    Lee S, Vasudevan S. Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol. 2013;768:97–126.PubMedCrossRefGoogle Scholar
  23. 23.
    Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Liu J, Zheng M, Tang YL, Liang XH, Yang Q. MicroRNAs, an active and versatile group in cancers. Int J Oral Sci. 2011;3:165–75.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Zeng Y, Qu X, Li H, Huang S, Wang S, Xu Q, et al. MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting bmpr2. FEBS Lett. 2012;586:2375–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, et al. Significance of plk1 regulation by mir-100 in human nasopharyngeal cancer. Int J Cancer. 2010;126:2036–48.PubMedGoogle Scholar
  27. 27.
    Oliveira JC, Brassesco MS, Morales AG, Pezuk JA, Fedatto PF, da Silva GN, et al. MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev. 2011;12:3001–4.PubMedGoogle Scholar
  28. 28.
    Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008;3:e2436.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jie Chen
    • 1
    • 2
  • Biqiang Zheng
    • 1
    • 2
  • Chunmeng Wang
    • 1
    • 2
  • Yong Chen
    • 1
    • 2
  • Chunyan Du
    • 1
    • 2
  • Guangfa Zhao
    • 1
    • 2
  • Ye Zhou
    • 1
    • 2
  • Yingqiang Shi
    • 1
    • 2
  1. 1.Department of Gastric Cancer and Soft Tissue SarcomasFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations